| Literature DB >> 35127957 |
Amit Kumar Tripathi1,2, Anup Kumar Ray3,4, Sunil Kumar Mishra3.
Abstract
BACKGROUND: Piperine is a type of amide alkaloid that exhibits pleiotropic properties like antioxidant, anticancer, anti-inflammatory, antihypertensive, hepatoprotective, neuroprotective and enhancing bioavailability and fertility-related activities. Piperine has the ability to alter gastrointestinal disorders, drug-metabolizing enzymes, and bioavailability of several drugs. The present review explores the available clinical and preclinical data, nanoformulations, extraction process, structure-activity relationships, molecular docking, bioavailability enhancement of phytochemicals and drugs, and brain penetration properties of piperine in the prevention, management, and treatment of various diseases and disorders. MAIN BODY: Piperine provides therapeutic benefits in patients suffering from diabetes, obesity, arthritis, oral cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Parkinson's disease, Alzheimer's disease, cerebral stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. The molecular basis for the pleiotropic activities of piperine is based on its ability to regulate multiple signaling molecules such as cell cycle proteins, anti-apoptotic proteins, P-glycoprotein, cytochrome P450 3A4, multidrug resistance protein 1, breast cancer resistance protein, transient receptor potential vanilloid 1 proinflammatory cytokine, nuclear factor-κB, c-Fos, cAMP response element-binding protein, activation transcription factor-2, peroxisome proliferator-activated receptor-gamma, Human G-quadruplex DNA, Cyclooxygenase-2, Nitric oxide synthases-2, MicroRNA, and coronaviruses. Piperine also regulates multiple signaling pathways such as Akt/mTOR/MMP-9, 5'-AMP-activated protein kinase-activated NLR family pyrin domain containing-3 inflammasome, voltage-gated K+ current, PKCα/ERK1/2, NF-κB/AP-1/MMP-9, Wnt/β-catenin, JNK/P38 MAPK, and gut microbiota. SHORTEntities:
Keywords: Anticancer; COVID-19; Clinical trials; Extractions; Gut microbiota; Pharmacokinetics; Piperine
Year: 2022 PMID: 35127957 PMCID: PMC8796742 DOI: 10.1186/s43088-022-00196-1
Source DB: PubMed Journal: Beni Suef Univ J Basic Appl Sci ISSN: 2314-8535
Members of Piperaceae family containing piperine [9]
| Name of plant | Part of plant | Piperine content (%) |
|---|---|---|
| Fruit | 1.7–7.4 | |
| Spike and root | 5–9 | |
| Fruit | 0.03 | |
| Fruit | 0.95–1.32 | |
| Fruit | 0.23–1.1 | |
| Root | 0.20 | |
| Stem | 1.59 | |
| Leaf | 0.104 | |
| Fruit | 2.75 |
Fig. 1A Structure; B–E Isomers of piperine [5]
Clinical trials on piperine*
| Condition & (number of patients) | Phases I, II, III or IV & (Status) | Dose, duration | Principal Investigator affiliation | Duration (months) | References |
|---|---|---|---|---|---|
KOA (60) | I (Completed) | 7.5 mg/day, 4 wks | Motahar Heidari-Beni, IUMS | Jan 2018–May 2018 (5) | Heidari-Beni et al. [ |
TCS 12) | I (Completed) | 20 mg/day,10 days | S. K. Bedada | 2016–2016 – | Bedada et al. [ |
MS (12) | I (Completed) | 20 mg/day, 2 days | HMO & A. Hoffman and A. Domb, DRBCPHU | Aug 2013–Jan 2015 (17) | Cherniakov et al. [ |
AIDS (08) | I (Completed) | 20 mg/day,7 days | Ravisekhar Kasibhatta, BCRPL, Hyderabad | 2007–2008 – | Kasibhatta and Naidu [ |
NAFLD (79) | III (Completed) | 5 mg/day, 8 weeks | Dr. Abasalt Borji, NUMS | Jan 2017–Nov 2017 (10) | Mirhafez et al. [ |
T2DM (100) | III (Ongoing) | 5 mg/day, 12weeks | Jun 2015–Present (12) | * | |
NAFLD (70) | II (Ongoing) | 5 mg/day, 12weeks | Jan 2018–Present – | ||
HIVS (60) | I (Completed) | – | Philip C Smith, School of Pharmacy, UNC Chapel Hill | Sep 2003–Mar 2006 (30) | |
MN, Pain, BS, Urinary Urgency (09) | I (Active, not recruiting) | – | Aminah Jatoi, Mayo Clinic, Rochester, Minnesota, United States | Mar 2016–Mar 2021 (60) | |
CKD (30) | NA (Recruiting) | 500 mg of curcumin and piperine, 3 capsules/day, 12 weeks | Denise Mafra, Federal University Fluminense, Rio de Janeiro, Brazil | Oct 2020–Oct 2021 (12) | |
Hair Thinning (70) | NA Recruiting) | 95% piperine extract in formulation, 4 capsules/ day, 180 days | Glynis Ablon, ABSIRC, Manhattan Beach, California, United States | Jun 2019–Jan 2021 (18) | |
Epilepsy (10) | I (Completed) | 20 mg/day, 2 days | Smita Pattanaik, NOD-PGIMER, Chandigarh, India | 2017–2017 – | Pattanaik et al. [ |
OD (40) | I&II (Completed) | Group1 = 150 μM Group 2 = 1 mM | Laia Rofes, GPLRU, Hospital de Mataro´, Spain | Jun 2011–Feb 2012 (9) | Rofes et al. [ |
MS (12) | I (Completed) | 20 mg/day, 10 days | S K Bedada, UCPSKU | 2016–2016 – | Bedada and Boga [ |
OA (53) | III (Completed) | 15 mg/day, 6 weeks | Dr. Yunes Panahi, CIRC-BUC, CRDU-BH, BUMS, Iran | Jan 2011–Jan 2012 (12) | Panahi et al. [ |
Vitiligo (63) | II&III (Completed) | 1% Topical solution, 12weeks | Anoosh Shafiee, SRC-SBUM, Iran | Jun 2016–Sep 2016 (3) | Shafiee et al. [ |
* Referenced from:—US National Library of Medicine: https://www.clinicaltrials.gov/ct2/results?cond=&term=piperine&cntry=&state=&city=&dist = ; University hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR): https://www.umin.ac.jp/ctr/index.htm & Iranian Registry of Clinical Trials: https://www.irct.ir/
Fig. 2Total number of publications of piperine in previous ten years.
Source: https://pubmed.ncbi.nlm.nih.gov/?term=PIPERINE&filter=datesearch.y_10&timeline=expanded
Fig. 3Targets of Piperine
Fig. 4Proposed scheme for signaling molecular target of piperine
Analogues and derivatives of piperine with their biological activity and mechanism of action
Methods of piperine extraction from black and white pepper
| Methods | Apparatus used | Extraction yield & (extraction time) | Solvent used | Advantage | Disadvantage | References |
|---|---|---|---|---|---|---|
| CHE | Soxhlet apparatus | 3.2% 2 h | 95% Ethanol,10% aq. Potassium hydroxide | Simple, low cost, no filtration is required after leaching | A long time of extraction and a large amount of extractant is required | Luque de Castro and Priego-Capote [ |
| Reflux Extraction | RBF, condenser, Buchner funnel, etc. | 5% 20 min | Dichloro-methane, Acetone and Hexane | More efficient than percolation or maceration and requires less extraction time and solvent | Cannot be used for thermolabile natural products | Shingate et al. [ |
| Cold Maceration | Separating funnel, Rota evaporator, etc. | 4.6% – | GAA, chloroform, 10% sodium bicarbonate, toluene, ethyl acetate, sodium hydroxide, diethyl ether | Yield is high, pure, and crystallizable as compared to the above two methods | Complex and time-consuming | Shingate et al. [ |
EASC-CO2 Extraction | SPEED SFE 2, Ice-bath | 0.88–1.38 mg/g dry black pepper 2.25 h | α-Amylase, CO2, methanol | Efficient | Expensive | Dutta and Bhattacharjee [ |
ILUA Extraction | KQ-100DA and KQ-500 ultrasonic water baths (Kunshan, Jiangsu, China), Acquity™ UPLC (Waters, Milford, MA, USA) | 3.57% 30 min | 1-Alkyl-3-methylimidazolium ionic liquids, deionized water, methanol | High extraction efficiency, and less extraction time | Expensive | Cao et al. [ |
| SLDE | Naviglio Extractor® | 317.7 mg/g 3 h | 96% Ethanol | Simple application, exhaustion in a short period, production of high-quality extracts | Expensive | Gigliarelli et al. [ |
| SMUAE | Microwave oven (CQ4250, Samsung) Ultrasonic bath (Elmasonic S10H) | 46.6 mg/g 31 min | Ethanol, Methanol, Acetone, Dichloromethane Potassium hydroxide, Hexane, Acetonitrile | Increased extraction efficiency | Not suitable for thermolabile natural products | Gorgani et al. [ |
| MAE | IFB domestic microwave oven (model Neutron) | 45% 4 h | Petroleum ether, water | Simple, rapid, and reliable | Not suitable for thermolabile natural products | Raman and Gaikar [ |
| UAE | – | 0.58% w/w 18 min | Ethanol, hexane, and acetone | Short running time, higher extractive yield, controllable parameters | Small particle size, more filtration steps | Shityakov et al. [ |
| SFE | – | 90–96% w/w 2–5 h | Liquid carbon dioxide | Efficient, selective, clean, fast | High cost, less pressure-resistant | Shityakov et al. [ |
Pharmacokinetics effect of piperine on different drugs
| Drug | Dose (Piperine + Drug, duration) | ROA | Methods of detection | Plasma level | References |
|---|---|---|---|---|---|
| Propranolol | 20 mg + 40 mg, 7 days | oral | Spectrofluorimetric method | 1000–1200 ng mL−1 h | Bano et al. [ |
| Theophylline | 20 mg + 150 mg, 7 days | Oral | EMIT | *80–90 μg mL−1 h | Bano et al. [ |
| Diclofenac | 20 mg + 100 mg, 10 days | Oral | NCAM, Phoenix WinNonlin 6.2 software | 7.09–11.81 μg mL−1 h | Satish Kumar Bedada et al. [ |
| CBZ | 20 mg + 200 mg, 10 days | Oral | NCAM, Phoenix®, WinNonlin 6.4® software | 40–70 μg mL−1 h | Bedada et al. [ |
| Emodin | 20 mg/kg + 20 mg/kg, 1 day | Oral | LC–MS/MS | 1913–2555 ng mL−1 h | Di et al. [ |
| Linarin | 20 mg/kg + 50 mg/kg, 1 day | Oral | NCAM, DAS 2.1.1 Software, ANOVA | 240–934 ng mL−1 h | Feng et al. [ |
| Curcumin | In rats-20 mg/kg + 2 g/kg, 1 day In humans- 5 mg + 500 mg, 1 day | Oral | MIM, PHARMKIT computer programme with SIMPLEX algorithm | 3.33–3.95 μg mL−1 h 0.07–0.09 μg mL−1 h | Shoba et al. [ |
| Cannabidiol | 10 mg/kg + 15 mg/kg, 10 days | Oral | NCAM, WinNonlin® (version 5.2, Pharsight, Mountain View, CA) | Acute- 576–610 Ng mL−1 h Chronic- 722–896 ng mL−1 h | Izgelov et al. [ |
| Fexofenadin | 10 mg/kg + 10 mg/kg 10 mg/kg + 5 mg/kg, 1 day | Oral oral + IV | NCAM, WinNonlin® (version 5.2, Pharsight, Mountain View, CA) | 687–1353 ng mL−1 h 5670–9830 ng mL−1 h | Jin and Han [ |
| Sodium valproate | 5 mg/kg + 150 mg/kg, 1 day | Oral | NCAM, trapezoidal method | 1024 μg mL−1.h | Parveen et al. [ |
| OXR | 10 mg/kg + 100 mg/kg 1 mg/kg + 10 mg/kg, 1 day | Oral IV | NCAM, PK Solution 2.0 software (Summit Research Service) | 9375.27 ± 1974.32 μg h/L 1471.00 ± 1945.62 μg h/L | Junsaeng et al. [ |
*Serum concentration
Pharmacokinetic parameters of piperine in human body
| Route of administration | Dose | AUC0−∞ | References | |||
|---|---|---|---|---|---|---|
| Oral | 24 | 3.77 ± 1.63 | 2.15 ± 1.21 | 58.41 ± 23.50 | 8.74 ± 8.95 | Itharat et al. [ |
| Oral | 20 | 290.00 ± 42.47 595.4 ± 108.6 | – – | 59.32 ± 10.82 15.79 ± 50.50 | 13.26 ± 1.91 15.82 ± 4.95 | Wen-xing [ |
| Oral | 20 | 290 ± 40 | 3.50 ± 1.78 | 5.93 ± 1.08 | 13.3 ± 1.9 | Ren and Zuo [ |
Pharmacokinetic parameters of piperine in rodents
| Route of administration | Dose | AUC0-∞ (μg h/mL) | References | |||
|---|---|---|---|---|---|---|
| Oral | 20 | 1.10 | 2.00 | 1.27 | 7.20 | Ren and Zuo [ |
| Oral | 54.4 | 4.29 ± 0.97 | 2.45 ± 2.12 | 4.10 ± 0.94 | 23.1 ± 0.1 | |
| Intravenous | 10 | 2.90 | – | 8 | 15.6 | |
| Intravenous | 3.5 | 5.90 ± 1.76 | – | 1.68 ± 0.40 | 3.80 ± 0.84 | |
| Intra-peritoneal | 20 | 0.051 ± 0.009 | 3.00 ± 0.17 | - | 1.22 |
Fig. 5Mechanistic effect of piperine for bioavailability enhancement of various drugs with pleiotropic mechanism